Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 4/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29064677 | 0.90 | KDM4E (0.34) | KDM4EKMT2AALDH1A1L3MBTL1MAOA | |
| SCHEMBL16469881 | 0.90 | KDM4E (0.32) | KDM4EKMT2AALDH1A1L3MBTL1MAOA | |
| SCHEMBL16470351 | 0.88 | MAPT (0.38) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16470209 | 0.88 | MAPT (0.42) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16470345 | 0.86 | MAPT (0.42) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16469846 | 0.86 | MAPT (0.40) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16470408 | 0.84 | MAPT (0.39) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16470410 | 0.83 | MAPT (0.44) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL16470287 | 0.80 | MAPT (0.41) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL29064665 | 0.78 | ALDH1A1 (0.35) | KDM4EMAPTKMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9386769-B2 | Thiazole methylamino pyridine compounds and preparation method therefor | HUNAN RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2016-07-12 | — | — | US | claimed |
| US-20150051402-A1 | Thiazole Methylamino Pyridine Compounds and Preparation Method Therefor | HUNAN RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2015-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051402-A1 | Thiazole Methylamino Pyridine Compounds and Preparation Method Therefor | NOTUM, WEE1, CYP51A1 | KDM4E 1004/4885MAPT 2642/4885KMT2A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.